Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
(feeds.content.dowjones.io)
1.
2.
Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree
(feeds.content.dowjones.io)
3.
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
(feeds.content.dowjones.io)
4.
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
(feeds.content.dowjones.io)